Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-ENSEMBLE: Ensartinib plus chemotherapy as neoadjuvant therapy in ALK-positive NSCLC
ChiCTR2500113689Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoints: Pathological complete response rate (pCR) and Impact of baseline ALK fusion with concurrent gene co-mutations on efficacy. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113689.